This week, we will discuss the use of 3K dialysis bath with sodium zirconium cyclosilicate versus 2K bath and no potassium lowering medications in dialysis patients and the associated risk of arrhythmia.
This week, we will discuss post-trial follow-up for EMPA-Kidney. What are the longer-term effects of empagliflozin for patients with chronic kidney disease?
Nausea is a very common and distressing problem. Some medications that treat nausea carry a higher risk for arrhythmias, like Torsades de Pointes, and sudden cardiac death. Is ondansetron safe for use in patients on hemodialysis?
This week, we will discuss non-steroidal mineralocorticoid antagonist in the multiverse of cardiovascular-kidney-metabolic. What FINEHEART pooled analysis would add to what we already learned from FIDELIO-DKD trial?
Tissue sodium excess is not hypertonic and reflects extracellular volume expansion (Rossitto, Nature Communications 2020)
Apart from the storify and transcript, don't miss the commentary from Rodby, and this summary from Paul Welling:
#nephjc A few final thoughts: pic.twitter.com/XdUZK1Z5K0
— Paul A Welling (@PaulAWelling1) June 7, 2017
